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Introduction: With improving survival of rectal cancer, functional outcome has become in-
creasingly important. Following sphincter-preserving resection many patients suffer from 
severe bowel dysfunction with an impact on quality of life (QoL) – referred to as low ante-
rior resection syndrome (LARS). 
Study objective: To provide an overview of the current knowledge of LARS regarding symp-
tomatology, occurrence, risk factors, pathophysiology, evaluation instruments and treat-
ment options. 
Results: LARS is characterized by urgency, frequent bowel movements, emptying diffi culties 
and incontinence, and occurs in up to 50-75% of patients on a long-term basis. Known risk 
factors are low anastomosis, use of radiotherapy, direct nerve injury and straight anasto-
mosis. The pathophysiology seems to be multifactorial, with elements of anatomical, sen-
sory and motility dysfunction. Use of validated instruments for evaluation of LARS is es-
sential. Currently, there is a lack of evidence for treatment of LARS. Yet, transanal irrigation 
and sacral nerve stimulation are promising. 
Conclusion: LARS is a common problem following sphincter-preserving resection. All pa-
tients should be informed about the risk of LARS before surgery, and routinely be screened 
for LARS postoperatively. Patients with severe LARS should be offered treatment in order 
to improve QoL. Future focus should be on the possibilities of non-resectional treatment in 
order to prevent LARS.
© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. 
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Resultados funcionais após tratamento de câncer retal
Introdução: Com o aumento da sobrevida após câncer retal, o resultado funcional se tornou 
cada vez mais importante. Após ressecção com preservação do esfíncter, muitos pacientes 
sofrem de disfunção intestinal com um impacto sobre a qualidade de vida (QdV) – denomi-
nada síndrome da ressecção anterior baixa (LARS). 
Objetivo do estudo: Fornecer uma visão geral do conhecimento atual da LARS com relação 
à sintomatologia, à ocorrência, aos fatores de risco, à fi siopatologia, aos instrumentos de 
avaliação e às opções de tratamento. 
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Resultados: A LARS é caracterizada por movimentos intestinais repentinos e frequentes, di-
ficuldades de esvaziamento e incontinência e ocorre em até 50-75% dos pacientes em longo 
prazo. Os fatores de risco conhecidos são anastomose baixa, radioterapia, lesão direta do 
nervo e anastomose direta. A fisiopatologia parece multifatorial, com elementos de disfun-
ção anatômica, sensorial e da motilidade. O uso de instrumentos validados para avaliação 
da LARS é essencial. Atualmente, não há comprovações de tratamento da LARS. Ainda hoje, 
a irrigação transanal e a estimulação do nervo sacral são comprometidas. 
Conclusão: A LARS é um problema comum após ressecção com preservação do esfíncter. 
Todos os pacientes devem ser informados sobre o risco de LARS antes da cirurgia, e o ras-
treamento da LARS deve ser rotineiro após a cirurgia. Pacientes com LARS severa devem 
receber tratamento para melhorar a QdV. O foco futuro deve ser nas possibilidades de tra-
tamento sem ressecção a fim de evitar a LARS.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. 
Introduction
Rectal cancer is a common disease worldwide with an in-
creasing incidence. During the last few decades, develop-
ment of new treatment strategies has resulted in markedly 
increased survival.
At present, surgical resection with radical removal of the 
tumor with curative intent is the primary treatment for most 
patients. Depending on the height of the tumor, the resection 
can be done as a sphincter-preserving resection (low anteri-
or resection, LAR) or an abdomino-perineal resection (APR).1 
Sphincter-preserving resection of rectal cancer, with the 
creation of a colorectal or coloanal anastomosis, follows the 
principle of total mesorectal excision (TME) as first described 
by Heald in 1982.2 Tumors located in the uppermost part of 
the rectum can be excised by a partial mesorectal excision 
(PME) with similar oncological results.3 APR is used in cases 
where the tumor is threatening the sphincter or when expec-
tations of creating an anastomosis with acceptable functional 
results are low. Within the last decades, the use of APR has 
decreased substantially, and several trials have investigated 
the possibility of creating ultra-low anastomoses with partial 
or full resection of the internal sphincter (ISR) to avoid a per-
manent abdominal colostomy.4,5
Unfortunately, many patients develop severe pelvic dys-
function following a sphincter-preserving resection of the rec-
tum. These include bowel, urinary and sexual dysfunctions.6-8 
Studies have shown that up to 25-50% of all patients expe-
rience major dysfunction on a daily basis with a significant 
impact on quality of life (QoL).9-12 The extent of these prob-
lems varies greatly with some patients obtaining near-normal 
function after a postoperative recovery of a few months, and 
others being severely disabled physically and socially for the 
rest of their lives.10,11
The increase in survival has led to an increased attention 
to the importance of functional outcome and QoL. Knowl-
edge of not only oncological, but also long-term functional 
outcome is essential for all colorectal surgeons in order to 
manage these patients, both in terms of choosing the optimal 
treatment option and in terms of managing the functional 
deficits after recovery.
Low anterior resection syndrome – LARS
Bowel dysfunction following LAR is often referred to as low 
anterior resection syndrome (LARS). Although recognized for 
years, a clear definition has not been established. Recently, Bry-
ant et al. proposed a very pragmatic definition: “disordered bowel 
function after rectal resection, leading to a detriment in quality of 
life”.13 LARS is characterized by urgency, frequent bowel move-
ments, emptying difficulties and incontinence for flatus and/
or feces.10,14 It is most pronounced during the first months af-
ter surgery, improves during the first year and reaches a steady 
state 1-2 years after surgery.
Bowel function after LAR has been investigated in several 
studies over the last decades, with large variations in the re-
ported frequency of symptoms. Some studies have shown that 
up to 75% of patients experience severe bowel dysfunction on a 
long-term basis following LAR.9,13,15 It has been established that 
LARS has a significant impact on overall QoL.11
The incontinence and urgency aspects of LARS have often 
been investigated, showing large variations in occurrences in 
different studies, ranging from 0-51% and 4-68% respective-
ly.16-18 Some studies have also investigated evacuation difficul-
ties, clustering and incomplete emptying, showing prevalences 
ranging from 2-74%.13
These large variations in the occurrence of symptoms are 
likely a result of inconsistent terminology, with unclear defini-
tions of symptoms and use of non-validated instruments. Nev-
ertheless, they could also reflect, to some extent, differences 
between study populations.
Incontinence is one of the most commonly reported symp-
toms after LAR. However, it seems that this symptom might not 
be very important for the patients with regards to impact on 
QoL. A recent study investigating health-related QoL and bowel 
function showed that there was a statistically significant as-
sociation between urgency and incomplete emptying and QoL, 
but not between incontinence and QoL. Similarly, in the devel-
opment of a new scoring system for LARS, it was shown that ur-
gency and clustering had a much higher impact on QoL than in-
continence.14 These results suggest that although incontinence 
occurs frequently after LAR, this symptom does not affect the 
patient’s life to the same degree as urgency and fragmentation.
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The reason for this might be that a patient can easily han-
dle an occasional incontinence episode, whereas the constant 
fear and uncertainty of never knowing when the urge might 
appear, thinking that you may need a toilet within minutes, 
and wondering if you will need a toilet again within a short 
interval, can be very incapacitating.
Numerous studies have examined QoL in rectal cancer pa-
tients, but most have focused on differences between treat-
ment options. Many studies have looked into QoL in LAR 
patients compared to APR patients, with confl icting results.1 
Generally, it seems that APR patients have lower QoL than 
LAR patients.
However, when investigating low rectal cancers within 
6 cm from the anal verge, this observation changes. Even 
though some areas of QoL appear to be worse in APR patients 
(sexual function and body image), these lower scores are well 
balanced by better QoL scores in the areas of cognitive and 
social functioning, as well as better symptom scales.19
Risk factors
Several factors are known to infl uence bowel function follow-
ing LAR. Patient factors such as age, gender and preoperative 
function have been suggested to be infl uential, although with 
confl icting results.10,20 However, tumor and treatment related 
factors seem more important for the development of LARS.
The level and stage of the tumor has been shown to be 
signifi cantly associated with function. Although many stud-
ies use the level of anastomosis as a surrogate marker for tu-
mor level, it appears to be of utmost importance for LARS.21 In 
particular, the very low cancers excised by ISR seem to yield a 
high risk of incontinence, soiling and urgency. 22 
The true effect of tumor stage is more diffi cult to assess 
because of potential confounding factors regarding treatment 
regimens. Generally, the more advanced tumors receive more 
chemo- and radiotherapy and may need more extensive dis-
section, thus increasing the risk of LARS.
It has been established that the use of both pre- and post-
operative radiotherapy (RT) with and without the addition of 
chemotherapy signifi cantly increases the risk of LARS.10,12,23,24 
Two large randomized controlled trials (RCTs) comparing 
preoperative RT and postoperative RT showed signifi cantly 
less acute and chronic gastrointestinal dysfunction, as well 
as lower local recurrence rates, in the preoperative group.25,26 
Therefore, the preoperative approach is most widely used to-
day.
Autonomic nerve-preservation is essential for preserving 
the pelvic functions, including sexual and bladder function. 
By careful dissection, sparing of the inferior mesenteric plexus, 
the superior and inferior hypogastric plexi, the hypogastric and pel-
vic splanchnic nerves, as well as the urogenital bundle at the 
levels of the prostate and the seminal vesicles, should be fea-
sible.27,28
Laparoscopic techniques have been introduced over the 
last decades and have shown promising results with regards 
to oncological, functional and QoL outcome.29,30 However, the 
long-term functional results still remain to be investigated.
Traditional teaching states that splenic fl exure mobiliza-
tion, including high ligation of the inferior mesenteric artery, 
is mandatory in rectal cancer surgery in order to achieve a 
satisfactory surgical and oncological outcome. Currently, this 
approach is under debate because of the lack of evidence.31,32
Some surgeons may use the sigmoid colon for the anas-
tomosis, thereby avoiding the risk of damage to the spleen 
associated with fl exure mobilization. However, the sigmoid is 
often affected by diverticulosis and/or muscular hypertrophy, 
and may therefore be less suitable for anastomosis.9,33 Further-
more, this method might lead to tension of the anastomosis, 
as well as compromising the blood supply to the sigmoid co-
lon during ligation of the inferior mesenteric artery, especially 
in cases of a small or non-existing Arcade  of Riolan, causing 
hypo-perfusion of the anastomosis. This might warrant mobi-
lization of the splenic fl exure and use of the descending colon 
for anastomosis.31 The functional results after reconstruction 
with the sigmoid or descending colon seem similar, although 
further studies are needed.33
A temporary diverting stoma is generally recommended 
in all lower anastomoses to decrease postoperative morbidity 
including clinical anastomotic leak, pelvic sepsis, postopera-
tive ileus and reoperation.34 The most frequently used stoma 
is the loop ileostomy, which is easy to fashion and to close, 
but it has been indicated that the loop transverse colostomy 
might lower the risk of intestinal obstruction and ileus after 
closure.35 Notwithstanding this, the functional consequences 
of a defunctioning stoma remain unclear. It has been shown 
that diversion can lead to stenosis of the anastomosis, atro-
phy or diversion colitis, with potential effects on functional 
outcome.36 More studies are needed to further elucidate this 
area.
Some studies have shown an increased risk of LARS after 
an anastomotic leakage, possibly due to increased fi brosis in-
duced by infl ammation, causing a reduced neorectal capacity 
and compliance.37
Surgical reconstruction
The type of anastomosis with or without the creation of a neo-
reservoir has been shown to be important for bowel function, 
although the effect seems to diminish over time.38,39 A neo-
reservoir can be constructed by a colonic J-pouch, a side-to-
end anastomosis a.m. Baker or a coloplasty (Fig. 1). Following 
TME surgery, the reservoir function of the rectum is destroyed 
and requires restoration. After PME surgery, at least part of the 
rectum remains and provides an acceptable neorectal reser-
voir, which is the reason why an end-to-end anastomosis can 
be chosen.10
Fig. 1 – Neo-reservoir types: Colonic J-pouch, side-to-end 
anastomosis and coloplasty.
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The colonic J-pouch is formed by folding a short segment 
of the distal colon and making a side-to-side anastomosis 
between the two loops using a linear stapler introduced 
through the apex of the pouch. The pouch is then connect-
ed to the rectal remnant by a circular stapled side-to-end 
anastomosis. This technique restores volume and has been 
shown to improve compliance and sensory function of the 
neorectum.39,40 Different sizes of pouches have been explored, 
and it has been shown that a pouch of 5-6 cm produces the 
best functional results, balancing the risk of urgency and fre-
quent stools in smaller pouches with the risk of emptying 
difficulties in larger pouches.4 Nonetheless, a customization 
of pouch size according to patient’s anal sphincteric func-
tion and tendency toward constipation or diarrhea might 
yield the best results. A weak sphincter and/or loose stool 
may suggest creating a larger pouch, while tendency of con-
stipation could suggest a smaller pouch for optimal results.9 
However, the evidence for this approach seems limited.
In some patients, a large voluminous colonic J-pouch 
might not be suitable or feasible: in a small narrow pelvis, 
or in patients without sufficient length of the colon. In these 
patients, a simple side-to-end anastomosis could be per-
formed, in which the side of the distal colon is anastomosed 
to the rectal remnant approximately 3-6 cm from the stapler 
line, on the antimesenterial side of the colon a.m. Baker.9,41 
Here, the blind distal end of the colon will eventually di-
late, hereby increasing the neorectal volume and changing 
the motility pattern of the neorectum. This neo-reservoir is 
easier to construct than the J-pouch and leaves fewer staple 
lines. The functional results of the side-to-end anastomosis 
seem comparable to those of the J-pouch, but larger stud-
ies are required to confirm this. Several trials have tested 
the transverse coloplasty pouch as an alternative to the J-
pouch, as it requires less space. The coloplasty is formed by 
a 7-10 cm long incision made along the antimesenterial side 
of the colon, a few cm above the distal end. The incision is 
closed transversally, creating a reservoir that is consequent-
ly connected to the rectal remnant by circular stapling. This 
results in a more voluminous neorectum with interrupted 
antegrade colonic peristalsis, and therefore better holding 
capacities.9,42 Some have found the functional results of 
the coloplasty comparable to the results after J-pouch, but 
a large RCT of long-term functional results and QoL two 
years after surgery showed that it had no advantages over 
the end-to-end anastomosis and was significantly inferior 
to the J-pouch.15 
In conclusion, in low anastomoses a colon J-pouch is su-
perior to the straight anastomosis, whereas the coloplasty 
has no advantages. The side-to-end anastomosis seems 
comparable to the J-pouch, but further studies are needed 
for validation. Currently, a large international multicenter 
RCT is comparing the long-term functional results of the 
side-to-end anastomosis and the colonic J-pouch.
Pathophysiology
Historically, the sphincter function and biomechanical prop-
erties of the neorectum has been seen as the most important 
factors in the development of LARS. Recently, more attention 
has been directed at the neurological damages after surgery 
and the effects on function, and a review in Lancet Oncology 
concluded that the syndrome seems to be multifactorial.13 
An increasing number of studies have investigated patho-
physiology and found that anatomical, sensory and muscu-
lar changes all seem likely to be involved. Neorectal capacity 
and compliance,43 sphincter function,44 pelvic floor function,13 
colonic motility45 and postprandial response46,47 have all been 
shown to be of importance. 
Yet, the precise pathophysiological mechanisms behind 
the syndrome remain unclear.
Several studies have found that diminished rectal capac-
ity and compliance are associated with poor functional out-
come.48 Previously, it was thought that the mere volume of 
the neorectal reservoir was of major importance and that this 
was the reason for the protective action of a reconstructed 
neorectum. More recently, it has been proposed that the effect 
is caused by a change in motility patterns in the neorectum 
rather than a volume increase.49
Some investigators have suggested that a low anorectal 
pressure gradient with high neorectal pressures, in combina-
tion with low sphincter pressures, is responsible for the in-
continence aspect of LARS.50
Recently, a study showed that careful preservation of the 
colonic and pelvic nerves can result in less fragmentation of 
stools.51 In high ligation of the inferior mesenteric artery and 
dissection of the lymph nodes close to the aorta, the extrinsic 
autonomic sympathetic nerves to the rectum and left side of 
the colon are resected, causing a sympathetically denervated 
colonic segment used for creation of the neorectum.52 This 
has been suggested to be a major cause of stool fragmenta-
tion, due to the missing negative feedback of the defecation 
reflex, causing an urge to defecate even when only small 
amounts of stools are present in the neorectum.51 Therefore, 
it has been suggested that resection with preservation of the 
left colonic artery might preserve autonomic function with-
out compromising oncological outcome.53 Recently, it was 
shown that patients with major LARS have an increased post-
prandial response, with significantly increased pressures in 
the neorectum after a minor meal compared to patients with 
no LARS, indicating a hyperactive postprandial response. This 
is possibly due to the lack of a sympathetic breaking action on 
colonic motility following the ingestion of a meal.47
The exact mechanisms for the detrimental effects of RT 
on bowel function remain unclear. Postoperative RT has been 
shown to cause lower sphincter pressures and induce fibrosis 
and rigidity in the neorectum, thereby affecting function sig-
nificantly.54 
However, with the use of preoperative RT, the neorectum 
is constructed from non-irradiated colon, and therefore is 
not directly affected by the RT. Nevertheless, preoperative RT 
still increases the risk of LARS significantly, possibly through 
fibrosis of the surrounding tissues, including nerves. It may 
also cause direct or indirect damage to the sphincters, even 
when the sphincters are excluded from the irradiation field.55 
Recently, it was shown that preoperative RT induces neorectal 
hyposensitivity to mechanical and thermal stimuli, possibly 
due to impaired afferent nerve function.56
In summary, physiological changes in motility and sensi-
bility seem to be the most important factors contributing to 
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the development of LARS, although biomechanical and ana-
tomical changes might also affect function. Further studies 
are needed to elucidate this subject.
Evaluation instruments
Studies investigating the functional disturbances after 
rectal cancer resection have used a large variety of non-
validated instruments. Function has often been described 
briefly as the proportion of patients experiencing incon-
tinence or urgency, and the mean number of daily bowel 
movements. Several attempts have been made to conduct a 
meta-analysis on the functional outcome after rectal cancer 
resection, but these have not be successful, due to differing 
terminology and scales used.
Many studies have focused mostly on the incontinence 
aspect of LARS, probably because of the number of incon-
tinence scores available and that fact that they are easy to 
use. Unfortunately, these scores only look into one facet of 
the LARS symptomatology and are not sufficient in describ-
ing the complex dysfunction.
In 2005, Temple et al. published a comprehensive scale 
developed to examine LARS.57 
The questionnaire consists of 18 questions and can be 
summed up into several subscales. This questionnaire cov-
ers all aspects of LARS, but is very time consuming for both, 
patients and doctors. Therefore, in our opinion, it is not very 
suitable for use in daily clinical practice.
In 2012, we published a new instrument for the evalua-
tion of LARS, called the LARS score. The LARS score consists 
of five simple questions, with score values directly corre-
lated with the impact on QoL.14 It was initially developed 
and validated in Danish, but has subsequently been trans-
lated and validated in several other languages, and is being 
used in a number of international trials.58 The LARS score 
has been proven to have a high sensitivity and specific-
ity for identifying patients with severe LARS. The benefit 
of this score is that it is easy to use in both research and 
clinical settings. Recently, we have shown that even rectal 
cancer experts do not have a thorough understanding of 
which LARS symptoms truly matter to the patient, nor how 
these symptoms affect QoL, thus underlining the necessity 
of using a validated instrument such as the LARS score to 
evaluate functional outcome according to the patient's per-
spective.59
Treatment of LARS
Unfortunately, there is no solid evidence-based treatment 
available for LARS. Although most colorectal centers have an 
increased awareness of the condition, treatment is rarely of-
fered to the many patients suffering from severe LARS. Re-
cently, a systematic review confirmed that conservative man-
agement of LARS can improve anorectal function and should 
be recommended as the first choice of treatment.60
Retrograde transanal irrigation (TAI), with instillation of 
lukewarm water into the gut via the anal canal, has been 
found to be effective in up to 79% of cases in smaller series.61,62 
In addition, sacral nerve stimulation (SNS) has proven to be 
effective in several small studies.63,64 However, both methods 
require further investigation, preferably in large RCTs, before 
general recommendations can be made.
Perspectives
Bowel dysfunction following sphincter-preserving resection 
for rectal cancer is a major problem, with almost half of the 
patients experiencing severe dysfunction on a daily basis 
with a significant impairment of quality of life.
With increasing incidence and survival of rectal cancer, 
the need for knowledge of the true extent of LARS is crucial 
for all colorectal surgeons. All patients should be thoroughly 
informed of the risk of LARS before surgery, and an individual 
risk evaluation should be performed. This recommendation 
is particularly important in low rectal cancers, where the 
choice between LAR and APR should be made based on the 
risk evaluation and patient preference after being adequately 
informed.
Given that neoadjuvant therapy (NT) has only limited ben-
efit on overall survival, but a detrimental effect on function, 
the selection of patients for NT should, in our opinion, be 
more conservative. Currently, many studies are investigating 
the potential molecular, biological, genetic and histological 
markers for the prediction of the effectiveness of RT. 
Once we can identify the tumors that are most responsive 
to radiotherapy, we can diminish the proportion of patients 
being “over-treated” with RT, where they experience no ben-
efit but only side effects.
However, resectional surgery is the major cause of LARS. 
With implementation of colorectal cancer screening pro-
grams, we hope that in the future, more rectal cancers will be 
curable with local excision only. Also, promising results are 
seen with identifying complete responders to chemoradio-
therapy and watchful waiting, which could render resectional 
therapy unnecessary. However, the functional outcome of this 
patient group remains to be investigated.
More studies are needed to elucidate the full pathophysi-
ology of LARS in order to further refine the surgical procedure 
and prevent severe dysfunction, possibly through a “sympati-
cus-preserving resection”.
All patients recovering after LAR should be routinely 
screened for LARS using a validated instrument. Functional 
outcome, as well as oncological outcome, should be system-
atically registered for all patients, in order to monitor the 
quality of any treatment they receive. This will yield a base-
line reference for new treatment modalities – both in terms 
of treatment of the cancer itself, and in terms of treatment of 
the functional disturbances.
All patients with severe LARS should be offered counsel-
ling and conservative treatment, or preferably be enrolled in 
trials investigating the effect of TAI or SNS or any other treat-
ment targeting LARS.
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